Management of Candida glabrata Positive Swab
The appropriate management depends critically on the clinical context: asymptomatic colonization (e.g., urine, respiratory tract) typically requires NO antifungal treatment, whereas invasive infection (candidemia, deep-seated abscess) mandates immediate echinocandin therapy as first-line treatment.
Clinical Context Determines Treatment Need
The fundamental decision point is distinguishing colonization from true infection:
When NOT to Treat
Candiduria (asymptomatic bladder colonization): Treatment with antifungal agents is NOT recommended unless the patient belongs to high-risk groups 1. The IDSA guidelines explicitly state that elimination of predisposing factors (particularly indwelling bladder catheters) is the primary intervention 1.
High-risk exceptions requiring treatment:
- Neutropenic patients
- Very low-birth-weight infants (<1500 g)
- Patients undergoing urologic manipulation 1
When TO Treat
Invasive infections require immediate antifungal therapy:
For Candidemia/Bloodstream Infection
An echinocandin is the first-line treatment (strong recommendation; high-quality evidence) 1:
- Caspofungin: 70 mg loading dose, then 50 mg daily
- Micafungin: 100 mg daily
- Anidulafungin: 200 mg loading dose, then 100 mg daily
This recommendation is particularly critical for C. glabrata given its intrinsic reduced susceptibility to fluconazole 1. Testing for azole susceptibility is recommended for all clinically relevant C. glabrata isolates 1.
Key management principles:
- Remove central venous catheters if present (strong recommendation) 1
- Obtain daily or every-other-day blood cultures until clearance 1
- Perform dilated ophthalmological examination within first week 1
- Continue therapy for 2 weeks after documented clearance and symptom resolution 1
For Cystitis (Symptomatic Lower UTI)
For fluconazole-resistant C. glabrata (which is common):
- Amphotericin B deoxycholate: 0.3–0.6 mg/kg daily for 1–7 days, OR
- Oral flucytosine: 25 mg/kg 4 times daily for 7–10 days 1
- Remove indwelling bladder catheter if feasible (strong recommendation) 1
Alternative: Amphotericin B deoxycholate bladder irrigation (50 mg/L sterile water daily for 5 days) may be useful 1.
For Pyelonephritis
For fluconazole-resistant C. glabrata:
- Amphotericin B deoxycholate: 0.3–0.6 mg/kg daily for 1–7 days with or without oral flucytosine 25 mg/kg 4 times daily 1
- Eliminate urinary tract obstruction (strong recommendation) 1
- Consider removal/replacement of nephrostomy tubes or stents 1
For Deep-Seated/Multidistrict Infections
Recent case reports demonstrate that combination therapy with echinocandin plus liposomal amphotericin B may be necessary when monotherapy fails, particularly in multidistrict infections where pharmacokinetic barriers limit single-agent effectiveness 2. This approach achieved microbiological clearance by day 20 in a complex case with persistent fungal growth despite echinocandin monotherapy 2.
For specific sites:
- Tubo-ovarian abscess: Caspofungin combined with surgical drainage 3
- Scrotal abscess: Liposomal amphotericin B (echinocandins have poor urogenital penetration) 4
- Empyema: Micafungin combined with pleural drainage 5
Critical Resistance Considerations
C. glabrata presents unique challenges:
- Intrinsic reduced azole susceptibility is common and increasing 6
- Echinocandin resistance is emerging but remains uncommon 6
- Amphotericin B and flucytosine remain mostly effective 6, 7
Recent surveillance from 2024 shows C. glabrata maintains high susceptibility to amphotericin B, echinocandins, and voriconazole, with uniform intermediate susceptibility to fluconazole 7.
Common Pitfalls to Avoid
- Do not treat asymptomatic candiduria in non-high-risk patients—this promotes resistance without benefit 1
- Do not use fluconazole as first-line for invasive C. glabrata given high resistance rates 1
- Do not assume echinocandins penetrate well into urinary tract—use amphotericin B formulations for genitourinary infections 4
- Do not delay source control—remove catheters, drain abscesses, address obstruction 1
Special Populations
For vulvovaginal candidiasis due to azole-resistant C. glabrata: